Valeant to take bid to shareholders after Allergan rejection

June 10 Tue Jun 10, 2014 11:08am EDT

June 10 (Reuters) - Allergan Inc's "inaccurate and misleading statements" and unsupported arguments about Valeant Pharmaceuticals Inc leaves Valeant no choice but to take its $53 billion takeover offer directly to Allergan shareholders, Valeant said on Tuesday.

Allergan's board has been unwilling to meet with Valeant, which it must do to properly gauge the value of Valeant's offer, spokeswoman Laurie Little said in a statement. Allergan rejected Valeant's most recent offer earlier in the day. (Reporting by Rod Nickel in Winnipeg, Manitoba)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.